Industry: Biological Region: Italy Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
An Italian biotechnology company, founded in 2018, uses artificial intelligence technology to design and develop bioactive peptides and peptidomimetics for life science and health technology.
Bioactive peptide is selective, effective and safe, and its good bioavailability makes it a reliable substitute for traditional therapeutic molecules, and it is easy to synthesize and optimize. The company solves problems by consulting and in-depth analysis of scientific literature, and provides customers with innovative solutions of bioactive peptides, which provides a basis for reasonable polypeptide design and provides treatment options for unmet medical needs.
Enterprise technical advantages:
1. Fast prediction speed
High-performance computers and powerful machine learning and molecular modeling algorithms can significantly reduce errors.
2. Continuous innovation
The company's technology platform can ensure that results can be achieved in just a few months, thus reducing research and development costs and shortening the time to market.
3. Targeted methods
Carry out on-demand research for specific goals to help customers make innovative solutions to recent or unsolved problems, so as to open up new markets.
4. Product innovation
Polypeptides, peptides and molecules provided to customers are unique, effective and patentable products.
Cooperation mode:
Seek partners who need bioactive peptide solutions in medicine, cosmetics, food and other fields.